Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat In Vitro

about

Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences.Darunavir–cobicistat–emtricitabine–tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era

P2860

Q38719799-3C04B039-2479-45B4-9FD6-EC51997DD7FF Q59126145-A2606F9D-3BD1-4A48-91EB-C567921721ED

P2860

Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat In Vitro

Item

http://www.wikidata.org/entity/Q38963389

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat In Vitro

@en

type

Item

label

Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat In Vitro

@en

prefLabel

Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat In Vitro

@en

P1476

Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat In Vitro

@en

P2093

Marco Siccardi

http://www.w3.org/2001/XMLSchema#string

Owain Roberts

http://www.w3.org/2001/XMLSchema#string

P2860

Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor.

Recent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: a Transition from Academic Curiosity to Regulatory Acceptance

Rationale and clinical utility of the darunavir-cobicistat combination in the treatment of HIV/AIDS

Simulation and prediction of in vivo drug metabolism in human populations from in vitro data

Modeling of rifampicin-induced CYP3A4 activation dynamics for the prediction of clinical drug-drug interactions from in vitro data

HIV and Tuberculosis: a Deadly Human Syndemic

Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers.

Predicting in vivo drug interactions from in vitro drug discovery data.

Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.

Prediction of hepatic clearance in human from in vitro data for successful drug development.

P31

scholarly article

P356

10.1128/AAC.01776-16

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Andrew Owen

S Khoo

P577

2017-04-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28193650

http://www.w3.org/2001/XMLSchema#string

P932

5404587

http://www.w3.org/2001/XMLSchema#string

Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat In Vitro

about

P2860

P2860

Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat In Vitro

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P31

P356

P407

P433

P478

P50

P577

P698

P932